29 May 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-asks-stealth-biotherapeutics-resubmit-application-rare-genetic-condition-2025-05-29/
29 Apr 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250429986004/en/Barth-Syndrome-Foundation-Calls-for-Urgent-FDA-Action-Following-Elamipretide-Delay
09 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-fda-advisory-committee-meeting-to-review-elamipretide-for-barth-syndrome-treatment-302242393.html
29 Jul 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-completes-mid-cycle-review-meeting-on-elamipretide-for-the-treatment-of-barth-syndrome-302207846.html
05 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-first-patient-enrolled-in-global-phase-3-clinical-program-for-elamipretide-in-patients-with-dry-age-related-macular-degeneration-302164947.html
07 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/stealth-biotherapeutics-barth-syndrome-nda-receives-priority-review-designation-302138192.html